Status:
COMPLETED
A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)
Lead Sponsor:
Eli Lilly and Company
Conditions:
Obesity
Overweight
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction.
Detailed Description
All enrolled participants will have completed SURMOUNT-5 (I8F-MC-GPHJ; NCT05822830) on treatment and meet further eligibility and randomization criteria. All endpoints for this study will be evaluated...
Eligibility Criteria
Inclusion
- Have completed the SURMOUNT-5 study on study treatment
Exclusion
- Have Type 1 Diabetes, Type 2 Diabetes, or any other types of diabetes, history of ketoacidosis, or hyperosmolar state/coma
- Have a prior or planned surgical treatment for obesity
- Have acute or chronic hepatitis
- Have a history of acute or chronic pancreatitis
Key Trial Info
Start Date :
September 13 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 21 2025
Estimated Enrollment :
376 Patients enrolled
Trial Details
Trial ID
NCT06584916
Start Date
September 13 2024
End Date
November 21 2025
Last Update
December 22 2025
Active Locations (29)
Enter a location and click search to find clinical trials sorted by distance.
1
Cahaba Research
Birmingham, Alabama, United States, 35242
2
Cahaba Research - Pelham
Pelham, Alabama, United States, 35124
3
Southern California Dermatology, Inc.
Santa Ana, California, United States, 92701
4
Encompass Clinical Research
Spring Valley, California, United States, 91978